Anavex Life Sciences Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
34
- Stock Symbol
-
AVXL
- Share Price
-
$0.93
- (As of Friday Closing)
Anavex Life Sciences General Information
Description
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Contact Information
Website
www.anavex.comCorporate Office
- 51 West 52nd Street
- 7th floor
- New York, NY 10019
- United States
Corporate Office
- 51 West 52nd Street
- 7th floor
- New York, NY 10019
- United States
Anavex Life Sciences Stock Performance
As of 13-Nov-2026, Anavex Life Sciences’s stock price is $0.93. Its current market cap is $86.5M with 92.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.93 | $0.99 | $0.92 - $5.36 | $86.5M | 92.7M | 1.04M | -$0.14 |
Anavex Life Sciences Financials Summary
As of 30-Jun-2026, Anavex Life Sciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 30-Sep-2025 | FY 2024 30-Sep-2024 | FY 2023 30-Sep-2023 |
|---|---|---|---|---|
| EV | 108,271 | 663,291 | 342,883 | 381,963 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (17,215) | (51,055) | (50,322) | (53,060) |
| Net Income | (13,022) | (46,377) | (43,002) | (47,505) |
| Total Assets | 120,139 | 103,815 | 135,567 | 154,386 |
| Total Debt | 0 | 0 | 0 | 0 |
Anavex Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Anavex Life Sciences Comparisons
Industry
Financing
Details
Anavex Life Sciences Competitors (39)
One of Anavex Life Sciences’s 39 competitors is Filana Therapeutics, a Formerly VC-backed company based in Austin, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Filana Therapeutics | Formerly VC-backed | Austin, TX | ||||
| BioCryst Pharmaceuticals | Corporation | Durham, NC | ||||
| Curemark | Venture Capital-Backed | New York, NY | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Mission Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom |
Anavex Life Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Anavex Life Sciences Patents
Anavex Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026221738-A1 | Responder selection and treatment with sigma-1 receptor therapy | Pending | 18-Apr-2025 | ||
| WO-2026015656-A1 | Responder selection and treatment with sigma-1 receptor therapy | Pending | 10-Jul-2024 | ||
| WO-2025264845-A1 | Use of anavex3-71 for medical treatments | Pending | 18-Jun-2024 | ||
| WO-2025231180-A1 | Blarcamesine correction of eeg biomarkers in fragile x syndrome | Pending | 01-May-2024 | ||
| WO-2025231180-A8 | Blarcamesine correction of eeg biomarkers in fragile x syndrome | Pending | 01-May-2024 | A61K31/341 |
Anavex Life Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Anavex Life Sciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.8 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Anavex Life Sciences FAQs
-
When was Anavex Life Sciences founded?
Anavex Life Sciences was founded in 2004.
-
Where is Anavex Life Sciences headquartered?
Anavex Life Sciences is headquartered in New York, NY.
-
What is the size of Anavex Life Sciences?
Anavex Life Sciences has 34 total employees.
-
What industry is Anavex Life Sciences in?
Anavex Life Sciences’s primary industry is Drug Discovery.
-
Is Anavex Life Sciences a private or public company?
Anavex Life Sciences is a Public company.
-
What is Anavex Life Sciences’s stock symbol?
The ticker symbol for Anavex Life Sciences is AVXL.
-
What is the current stock price of Anavex Life Sciences?
As of 13-Nov-2026 the stock price of Anavex Life Sciences is $0.93.
-
What is the current market cap of Anavex Life Sciences?
The current market capitalization of Anavex Life Sciences is $86.5M.
-
Who are Anavex Life Sciences’s competitors?
Filana Therapeutics, BioCryst Pharmaceuticals, Curemark, ACADIA Pharmaceuticals, and Mission Therapeutics are some of the 39 competitors of Anavex Life Sciences.
-
What is Anavex Life Sciences’s annual earnings per share (EPS)?
Anavex Life Sciences’s EPS for 12 months was -$0.14.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
